1. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev [Internet]. 2016;(4). Available from: https://doi.org/10.1002/14651858.CD001750.pub4
2. Hg A, Mafm Y, Aboulghar M, Fj B, Jg S. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology (Review) Summary of Findings for the Main Comparison. 2016;(5).
3. M.A Y and FV der V and HGA-I and GG and MHM and IA and SMK and M van W, M.A. Y, F. V der V, H.G. A-I, G. G, M.H. M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev [Internet]. 2011;1(10):CD008046. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008046.pub4/epdf/full
4. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle- stimulating hormone. Fertil Steril. 2001;75(3):519–24.
5. Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J, Uzan S. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril. 2004;82(1):119–25.